東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Druggable lipid signaling pathways

Kihara, Yasuyuki.

FindBook

Google Book

Amazon

博客來

Druggable lipid signaling pathways

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Druggable lipid signaling pathways/ edited by Yasuyuki Kihara.
其他作者:	Kihara, Yasuyuki.
出版者:	Cham :Springer International Publishing : : 2020.,
面頁冊數:	vi, 260 p. :ill., digital ;24 cm.
內容註:	Preface -- Introduction of Druggable Lipid Signaling Pathway -- Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Development -- Druggable Prostanoid Pathway -- Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress -- Epoxy Fatty Acids are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation -- Druggable Sphingolipid Pathway -- Druggable Lysophospholipid Pathway -- Druggable targets in endocannabinoid signaling -- Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections -- Druggable Lipid GPCRs: Past, Present, and Prospects.
Contained By:	Springer Nature eBook
標題:	Lipids. -
電子資源:	https://doi.org/10.1007/978-3-030-50621-6
ISBN:	9783030506216

Druggable lipid signaling pathways
Druggable lipid signaling pathways[electronic resource] /edited by Yasuyuki Kihara. - Cham :Springer International Publishing :2020. - vi, 260 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.12740065-2598 ;. - Advances in experimental medicine and biology ;v.1274..

Preface -- Introduction of Druggable Lipid Signaling Pathway -- Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Development -- Druggable Prostanoid Pathway -- Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress -- Epoxy Fatty Acids are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation -- Druggable Sphingolipid Pathway -- Druggable Lysophospholipid Pathway -- Druggable targets in endocannabinoid signaling -- Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections -- Druggable Lipid GPCRs: Past, Present, and Prospects.

This edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs.

ISBN: 9783030506216

Standard No.: 10.1007/978-3-030-50621-6doiSubjects--Topical Terms:

558980
Lipids.

LC Class. No.: QP751 / .D784 2020

Dewey Class. No.: 612.01577

Druggable lipid signaling pathways
LDR:02980nmm a2200349 a 4500 001 2243394
003 DE-He213
005 20201231092236.0
006 m d
007 cr nn 008maaau
008 211207s2020 sz s 0 eng d
020 $a 9783030506216 $q (electronic bk.)
020 $a 9783030506209 $q (paper)
024 7 $a 10.1007/978-3-030-50621-6 $2 doi
035 $a 978-3-030-50621-6
040 $a GP $c GP
041 0 $a eng
050 4 $a QP751 $b .D784 2020
072 7 $a MBGR $2 bicssc
072 7 $a SCI049000 $2 bisacsh
072 7 $a MBGR $2 thema
072 7 $a PSD $2 thema
082 0 4 $a 612.01577 $2 23
090 $a QP751 $b .D794 2020
245 0 0 $a Druggable lipid signaling pathways $h [electronic resource] / $c edited by Yasuyuki Kihara.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a vi, 260 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1274
505 0 $a Preface -- Introduction of Druggable Lipid Signaling Pathway -- Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Development -- Druggable Prostanoid Pathway -- Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress -- Epoxy Fatty Acids are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation -- Druggable Sphingolipid Pathway -- Druggable Lysophospholipid Pathway -- Druggable targets in endocannabinoid signaling -- Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections -- Druggable Lipid GPCRs: Past, Present, and Prospects.
520 $a This edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs.
650 0 $a Lipids. $3 558980
650 0 $a Cellular signal transduction. $3 600648
650 0 $a Pharmacology. $3 634543
650 0 $a Molecular biology. $3 517296
650 0 $a Diagnosis, Laboratory. $3 610896
650 0 $a Human genetics. $3 518846
650 0 $a Cancer $x Research. $3 696466
650 1 4 $a Molecular Medicine. $3 890952
650 2 4 $a Pharmacology/Toxicology. $3 890953
650 2 4 $a Laboratory Medicine. $3 894271
650 2 4 $a Human Genetics. $3 891169
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Lipidology. $3 907966
700 1 $a Kihara, Yasuyuki. $3 3503428
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Advances in experimental medicine and biology ; $v v.1274. $3 3503429
856 4 0 $u https://doi.org/10.1007/978-3-030-50621-6
950 $a Biomedical and Life Sciences (SpringerNature-11642)